The Journal of Rheumatology 2023;50:934–8
doi:10.3899/jrheum.220773
First Release February 15 2023

The Journal of Rheumatology

Patient Care Pathways for Pregnancy in Rare and Complex Rheumatic Diseases: Results From an International Survey

Chiara Tani[1], Dina Zucchi[2], Elisa Bellis[3], Mehret Birru Talabi[4], Charlotte Frise[5], Guilherme Ramires de Jesús[6], Hege Svean Koksvik[7], Gema Maria Lledó[8], Arsène Mekinian[9], Diana Marinello[10], Ilaria Palla[11], Puja Mehta[12], Luis Sáez Comet[13], Shoela Shaimaa[14], Hieronymus T.W. Smeele[15], Rosaria Talarico[1], Antonio Brucato[16], Munther Khamashta[17], Yehuda Shoenfeld[18], Angela Tincani[19], and Marta Mosca[1]

ABSTRACT. ***Objective.*** To map existing organizational care pathways in clinical centers of expertise that care for pregnant women affected by rare and complex connective tissue diseases (rcCTDs).

Methods. An international working group composed of experts in the field of pregnancy in rcCTDs co-designed a survey focused on organizational aspects related to the patient's pathway before, during, and after pregnancy. The survey was distributed to subject experts through referral sampling.

Results. Answers were collected from 69 centers in 21 countries. Patients with systemic lupus erythematosus and/or antiphospholipid syndrome were followed by more than 90% of centers, whereas those with disorders such as IgG4-related diseases were rarely covered. In the majority of centers, a multidisciplinary team was involved, including an obstetrician/gynecologist in 91.3% of cases and other healthcare professionals less frequently. Respondents indicated that 96% of the centers provided routine pre-pregnancy care, whereas the number of patient visits during pregnancy varied across centers. A formalized care pathway was described in 49.2% of centers, and 20.3% of centers had a predefined protocol for the monitoring of pregnant patients. Access to therapies during pregnancy also was heterogeneous among different centers.

Conclusion. In international referral centers, a high level of care is provided to patients with rcCTDs before, during, and after pregnancy. No significant discrepancies were found between European and non-European countries. However, this work highlights a potential benefit to streamlining the care approaches across countries to optimize pregnancy and perinatal outcomes among patients with rcCTDs.

Key Indexing Terms: complex diseases, pregnancy, rare diseases

[1]C. Tani, MD, PhD, R. Talarico, MD, PhD, M. Mosca, MD, PhD, Rheumatology Unit, Azienda Ospedaliero Universitaria Pisana and Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy; [2]D. Zucchi, MD, Rheumatology Unit, Azienda Ospedaliero Universitaria Pisana and Department of Clinical and Experimental Medicine, University of Pisa, Pisa, and Department of Medical Biotechnologies, University of Siena, Siena, Italy; [3]E. Bellis, MD, Rheumatology Unit, Mauriziano Umberto I Hospital, Turin Italy, and Rheumatology Unit, University and IRCCS Policlinico S. Matteo Foundation, Pavia, Italy; [4]M. Birru Talabi, MD, PhD, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA; [5]C. Frise, MD, Oxford University Hospitals NHS Foundation Trust, Oxford, UK; [6]G.R. de Jesús, MD, Universidade do Estado do Rio de Janeiro, Rio de Janeiro, Brazil; [7]H.S. Koksvik, MD, Norwegian National Advisory Unit on Pregnancy and Rheumatic Diseases, St. Olavs Hospital, Trondheim University Hospital, Trondheim, Norway; [8]G.M. Lledó, MD, Department of Autoimmune Diseases, Hospital Clinic, University of Barcelona, Barcelona, Spain; [9]A. Mekinian, MD, Sorbonne University, Internal Medicine Department, Saint Antoine Hospital, Paris, France; [10]D. Marinello, Rheumatology Unit, Azienda Ospedaliero Universitaria Pisana, University of Pisa, Pisa, Italy; [11]I. Palla, Institute of Management, Scuola Superiore Sant'Anna, Pisa, Italy; [12]P. Mehta, MD, Centre for Inflammation and Tissue Repair, UCL Respiratory, University College London, London, UK; [13]L.S. Comet, MD, Unidad de Enfermedades Autoinmunes Sistémicas, Servicio de Medicina Interna, Hospital Universitario Miguel Servet, Zaragoza, Spain; [14]S. Shaimaa, MD, Internal Medicine & Rheumatology Department, Alexandria Faculty of Medicine, Alexandria, Egypt; [15]H.T.W. Smeele, MD, Department of Rheumatology, Erasmus MC, Rotterdam, the Netherlands; [16]A. Brucato, MD, Università di Milano, Department of Biomedical and Clinical Sciences, Milan, Italy; [17]M. Khamashta, MD, PhD, Department of Women and Children's Health, King's College London, London, UK, and Gulf Medical Expert-Lupus, GSK, Dubai, UAE; [18]Y. Shoenfeld, MD, FRCP, Ariel University, Ariel, Israel; [19]A. Tincani, MD, Unit of Rheumatology and Clinical Immunology, ASST Spedali Civili di Brescia, Brescia, Italy.

MK is a full-time employee at and has received shares from GSK. The remaining authors declare no conflicts of interest relevant to this article.

Address correspondence to Dr. M. Mosca, MD, PhD, Rheumatology Unit, Department of Clinical and Experimental Medicine, University of Pisa, Via Roma 67, 56126, Pisa, Italy. Email: marta.mosca@med.unipi.it.

Accepted for publication December 16, 2022.

© 2023 The Journal of Rheumatology

Downloaded on October 6, 2026 from www.jrheum.org

As rare and complex connective tissue diseases (rcCTDs) frequently affect women of childbearing age, pregnancy and family planning are important facets of rheumatology and interdisciplinary care. rcCTDs may worsen in the context of pregnancy, leading to severe maternal morbidity and mortality or to fetal loss. Moreover, many people with childbearing capacity are routinely prescribed teratogenic antirheumatic drugs, increasing the risk of fetal death, congenital anomalies, or neurodevelopmental sequelae.

For decades, women with rcCTDs were advised not to become pregnant to avoid adverse pregnancy and perinatal outcomes. However, with advancements in diagnosis and treatment of rcCTDs, as well as in obstetric and neonatal care, people with rcCTDs are increasingly having safe and healthy pregnancies, particularly if their diseases are well controlled prior to and during pregnancy with pregnancy-compatible medications. Studies indicate that a rising number of women with rcCTDs are becoming pregnant, underscoring the need to develop clear guidelines and clinical pathways to address the potential health risks and challenges of these pregnancies.[1-4]

Several international rheumatology societies have developed recommendations for the management of pregnancy, family planning, and other aspects of reproductive health in patients with rheumatic diseases.[5,6] However, at sites where clinical rheumatology care is delivered, uniformly accepted and validated protocols for women affected by rcCTDs are rarely available; however, how to implement evidence-based recommendations around reproductive health effectively in clinical practice is yet unknown. Moreover, evidence-based data on pregnancy management of the rarer rheumatologic conditions, such as inflammatory myopathy and systemic sclerosis, are scarce and often based on case series or small observational studies.

Consequently, in real-life settings, the physician's experience and judgment often guide the management of pregnancy care, leading to significant heterogeneity and potential fragmentation in the patient's pregnancy care across different clinical disciplines.

During the 11th International Conference on Reproduction Pregnancy and Rheumatic Diseases,[7] a steering committee (SC) composed by MM, YS, AB, MK, and CT, proposed a project aimed at creating a consensus-based, clear, and well-defined care pathway model for pregnancy and reproductive issues in patients with rcCTDs to improve the quality of pregnancy-related health care, clinical outcomes, and patient experience.

Herein, we sought to describe existing organizational care delivery models offered to pregnant patients with rcCTDs across different clinical settings and countries to highlight strengths and areas for future improvement.

METHODS

The working group (WG) was composed of the SC members and a multidisciplinary international panel of experts in the field of pregnancy in rheumatic diseases. The University of Pisa coordinated the project.

The methods of this study were inspired by the RarERN Path,[8,9] a methodology specifically designed for the development of a common and shared organizational reference patient care pathway model for rcCTDs.

Framed by the RarERN methodology, the WG designed a survey that focused on specific organizational aspects related to the healthcare delivery pathways of people with rcCTDs immediately prior to, during, and after pregnancy.

The WG decided to prioritize rcCTDs that are either associated with adverse pregnancy outcomes or for which an evidence basis for pregnancy management is limited: antiphospholipid syndrome and antiphospholipid antibody carriers (APS), Behçet disease (BD), idiopathic inflammatory myopathy (IIM), IgG4-related disease (IgG4-RD), large-vessel vasculitides (LVV), mixed connective tissue disease (MCTD), relapsing polychondritis (RP), Sjögren syndrome (SS), small-vessel vasculitides (SVV), systemic lupus erythematosus (SLE), systemic sclerosis (SSc), and undifferentiated connective tissue disease (UCTD).

We decided to include rare and complex diseases and no other categories such as inflammatory arthritis, since the former share common management aspects, and should be taken care of by a multidisciplinary team.

The survey assessed 3 different phases of the patient's care pathway: pre-pregnancy counseling, monitoring/follow-up of the pregnancy, and postpartum care.

The survey was launched through the platform EUSurvey (https://ec.europa.eu/eusurvey/runner/rheumapregRarERNPath) and was active from June 20 to July 20, 2021.

Referral sampling was used to identify clinicians involved in the management of pregnancy-related issues in rcCTDs; these individuals were invited to participate by email. In addition, authors circulated the invitation in their network of colleagues. Only 1 questionnaire was completed per center. The answers were evaluated using descriptive statistics.

Statement of ethics and consent. An ethics committee approval was not needed since the survey was completely anonymous and completed by clinicians, and patients were not recruited. We obtained the survey participants' written informed consent to publish the material.

RESULTS

A total of 69 responses were collected from centers in 21 countries (Argentina, Austria, Brazil, Canada, China, France, Germany, India, Italy, Netherlands, Norway, Peru, Poland, Portugal, Qatar, Romania, Spain, Switzerland, UK, Ukraine, USA); 54 were European centers, 27 of which from Italy.

Clinicians from more than 80% of the centers reported that they cared for patients with SLE, APS, SS, UCTD, MCTD, and SSc during pregnancy. In contrast, pregnant patients with RP, IgG4-RD, IIM, and BD were followed in less than 63% of centers (Figure).

In the majority of the centers (88.1% in Italy, 80.3% outside Italy, 73.2% outside the EU), the pregnancy clinic involved multidisciplinary providers, including gynecologists/obstetricians in 91.3% of centers and, less frequently, other healthcare professionals, as detailed in Table 1. However, the disciplines included in the multidisciplinary teams were formalized in only 30.4% of the cases.

Regular pre-pregnancy care was performed in 96% of cases (96.2% in Italy, 95.2% outside Italy, 93.4% outside the EU), and the most frequent referrals for pre-pregnancy care were to a gynecologist/obstetrician working in the same hospital (76.8%) and/or other rheumatologists working outside or inside the team (71.0% and 69.5%, respectively). In 63.7% of centers, patients were referred to general practitioners for pre-pregnancy care.

Joint consultations with a rheumatologist and obstetrician/gynecologist were regularly conducted in 43.3% of centers

Downloaded on October 6, 2026 from www.jrheum.org



Figure. Diseases followed in pregnancy clinics. APS: antiphospholipid syndrome and aPL carriers; BD: Behçet disease; IgG4: IgG4-related disease; IIM: idiopathic inflammatory myopathy; LVV: large-vessel vasculitides; RP: relapsing polychondritis; SLE: systemic lupus erythematosus; SS: Sjögren syndrome; MCTD: mixed connective tissue disease; SSc: systemic sclerosis, SVV: small-vessel vasculitides; UCTD: undifferentiated connective tissue disease.

Table 1. Healthcare professionals (HCPs) involved in the multidisciplinary team and treatments prescribed in pregnancy clinics.

HCPs involved in the multidisciplinary team	%
Gynecologist/obstetrician	91.3
Nephrologist	49.2
Midwife	18.8
Psychologist	15.9
Nutritionist	7.2
Other dedicated HCPs[a]	24.6
Other	31.8
Centers with ability to prescribe treatments during pregnancy	
Low-dose aspirin	100
Glucocorticoids	98.5
Low molecular weight heparin	95.6
Antimalarials	94.2
Azathioprine	92.7
Biologics	79.7
IVIG	78.2
Cyclosporin	75.3
Tacrolimus	62.3
Other treatments	11.5

[a] HCP includes nurse and social worker. IVIG: intravenous Ig.

Table 2. Frequency of rheumatologist visits in pregnancy clinics.

Frequency of monitoring/follow-up rheumatologist visits during pregnancy	%
Every month	31.8
It is variable depending on the clinical picture but not less than every 2 months	28.9
It is variable depending on the clinical picture but not less than 3 months	18.8
One visit per trimester	10.1
Every 3 months	4.3
Every 2 months	2.8
With same frequency as outside pregnancy (ie, every 6 months)	0
When does the postpartum visit occur?	
Within 4 weeks of delivery	36.2
Within 8 weeks of delivery	33.3
Within 12 weeks of delivery	14.5
No answer	7.2
Within 2 weeks of delivery	5.8
Within 6 months of delivery	2.9

(48.4% Italy, 40.1% outside Italy, 33.3% outside the EU). The time of the patient's first appointment to a multidisciplinary pregnancy clinic was variable: at the time of positive pregnancy test in 47.8%, within first 8 weeks of gestation in 33.3%, and within first 12 weeks of gestation in 18.8%. The frequency of monitoring and/or follow-up visits and postpartum visit was also variable between centers, as detailed in Table 2. A formalized pregnancy care pathway for people with rcCTDs was present in 49.2%, and a predefined protocol/checklist for the monitoring of the patients during pregnancy was used in 20.3% of centers and in the postpartum period in 18.8% of centers.

Access to pregnancy-compatible rcCTD treatments during pregnancy seemed to be heterogeneous among different centers, especially with respect to cyclosporin, tacrolimus, biologics (eg, tumor necrosis factor inhibitors) and intravenous Ig. Available treatments at the various centers are summarized in Table 1.

DISCUSSION

This study sought to describe the existing patient care pathways that are in place in international centers of expertise that provide care for pregnant women affected by rcCTDs. From the survey, it appeared that most centers provided care for patients with rcCTDs before, during, and after pregnancy. No significant discrepancies were found among Italy, other European countries, and non-European Countries. However, a certain degree of fragmentation in healthcare practices emerged among different centers, underscoring the potential benefits of streamlining resources to improve patient care and outcomes.

Downloaded on October 6, 2026 from www.jrheum.org

First, although rheumatologists/immunologists/internal medicine subspecialists and obstetrician/gynecologists were always represented in the multidisciplinary teams, few other healthcare professionals were involved in the pregnancy clinics. rcCTDs are often systemic diseases that affect end organs, providing a rationale to include subspecialists from other disciplines (eg, gastroenterology, nephrology, cardiology). This is not surprising and is similar to other more common medical conditions in pregnancy for which multidisciplinary team management is recommended to reduce the occurrence of adverse maternal and fetal outcomes.[10] We also noted that approximately half of the centers did not facilitate joint consultations with the rheumatologist and the obstetrician/gynecologist; however, joint consultations might facilitate close communication about patient care, ensure that patients receive consistent medical advice and recommendations, and provide convenience for patients. Because this survey was conducted among experts in reproductive rheumatology who care for patients at specialized centers, it is reasonable to infer that in nonreferral centers, the frequency of joint rheumatology-obstetrics/gynecology consultations would be even lower.

Many centers also did not have a formalized care pathway or defined protocols for pre-pregnancy planning that might lead to better pregnancy and fetal outcomes, including supplementation with folic acid, smoking cessation, and switching from teratogenic medications to pregnancy-compatible antirheumatic drugs. Many centers also lacked protocols and checklists for standard pregnancy care to ensure monitoring of disease activity and/or potential complications specific to rcCTDs such as congenital heart block from SSA/Ro-antibodies. Some of the heterogeneity in pregnancy-related and fetal outcomes that have been observed in the literature may arise from the variation in pre-pregnancy and pregnancy care pathways. The availability of structured clinical pathways to guide patient care is also an important strategy to ensure effective knowledge transfer and sharing among clinicians, as well as to promote standardized evidence-based practices that are critical to facilitate better pregnancy outcomes among people with rcCTDs. For example, Wind et al[11] recently demonstrated a significant reduction in maternal complications in patients with SLE/APS that were managed within a structured multidisciplinary clinical pathway compared to a cohort of patients that was not managed in a clinical pathway.

Formalized clinical pathways might also help promote the delivery of high-quality, accessible and cost-effective healthcare for all patients with rcCTDs. The RarERN Path methodology provides a robust methodological framework for this project, as it integrates the perspectives of large communities of patients, expert clinicians, health economists, and healthcare providers from different EU countries.

Finally, it is important to note that the questionnaire was filled in by physicians mainly from high-income countries. Many countries around the world lack rheumatologists or clinicians to diagnose and care for people with rcCTDs, let alone to care for these patients during pregnancy. Further, many centers across the world lack the ability and/or experience to prescribe biologics, intravenous Ig, and some traditional immunosuppressants during pregnancy. The results confirm significant disparities in access to care and medications among different centers and underscore that access to high-quality care is a challenge for many patients with rcCTDs.[12,13]

This study has several limitations. The survey did not elicit information on the clinical background and expertise of the respondents. As the RheumaPreg scientific network was the main source of survey respondents, one of the most significant limitations of our survey might be the potential for sampling bias. Most of the people who responded to the survey were experts in reproductive rheumatology, which suggests that they are practicing at clinical centers that support their expertise. These respondents may be more likely than other rheumatologists to practice in healthcare systems that have established models of care for the reproductive health needs of patients with rcCTDs. Thus, these results are not generalizable, as they may not accurately reflect clinical practices in nonreferral centers.

Another limitation of our study was that more centers in Italy were represented among the survey respondents than in the study centers in any other country. However, we did not find significant differences in answers from Italy with respect to European and non-European countries.

In conclusion, our study represents the first evaluation, to our knowledge, of reproductive healthcare models of care in Europe and outside of Europe. Our findings highlight the need to streamline the reproductive health care provided among different countries, to ensure that all patients with rcCTDs receive consistent and high-quality reproductive health care. A shared organizational model may also create a more efficient use of resources, allowing clinicians from around the world to determine what models of care are most effective at caring for patients with rcCTDs. Indeed, organization always matters in health systems, especially when approaching rare and complex diseases and in specific health contexts such as pregnancy.

REFERENCES

1. Zucchi D, Tani C, Monacci F, et al. Pregnancy and undifferentiated connective tissue disease: outcome and risk of flare in 100 pregnancies. Rheumatology 2020;59:1335-9.
2. Tani C, Zucchi D, Haase I, et al. Are remission and low disease activity state ideal targets for pregnancy planning in systemic lupus erythematosus? A multicentre study. Rheumatology 2021; 60:5610-9.
3. Tincani A, Dall'Ara F, Lazzaroni MG, et al. Pregnancy in patients with autoimmune disease: a reality in 2016. Autoimmun Rev 2016;15:975-7.
4. Gupta S, Gupta N. Sjögren syndrome and pregnancy: a literature review. Perm J 2017;21:16-047.
5. Andreoli L, Bertsias GK, Agmon-Levin N, et al. EULAR recommendations for women's health and the management of family planning, assisted reproduction, pregnancy and menopause in patients with systemic lupus erythematosus and/or antiphospholipid syndrome. Ann Rheum Dis 2017;76:476-85.
6. Sammaritano LR, Bermas BL, Chakravarty EE, et al. 2020 American College of Rheumatology Guideline for the Management of Reproductive Health in Rheumatic and Musculoskeletal Diseases. Arthritis Care Res 2020;72:461-88.

Downloaded on October 6, 2026 from www.jrheum.org

7. 11th International Conference on Reproduction Pregnancy and Rheumatic Diseases. [Internet. Accessed January 16, 2023.] Available from: https://www.rheumapreg2021.com
8. Talarico R, Cannizzo S, Lorenzoni V, et al. RarERN Path: a methodology towards the optimisation of patients' care pathways in rare and complex diseases developed within the European Reference Networks. Orphanet J Rare Dis 2020;15:347. Erratum in: Orphanet J Rare Dis 2021;16:146.
9. European Reference Networks. ReCONNET. [Internet. Accessed January 16, 2023.] Available from: https://reconnet.ern-net.eu
10. Taylor C, McCance DR, Chappell L, et al. Implementation of guidelines for multidisciplinary team management of pregnancy in women with pre-existing diabetes or cardiac conditions: results from a UK national survey. BMC Pregnancy Childbirth 2017;17:434.
11. Wind M, Hendriks M, van Brussel BTJ, et al. Effectiveness of a multidisciplinary clinical pathway for women with systemic lupus erythematosus and/or antiphospholipid syndrome. Lupus Sci Med 2021;8:e000472.
12. Bergstra SA, Branco JC, Vega-Morales D, et al. Inequity in access to bDMARD care and how it influences disease outcomes across countries worldwide: results from the METEOR-registry. Ann Rheum Dis 2018;77:1413-20.
13. Minhas D, Marder W, Harlow S, et al. Access and cost-related nonadherence to prescription medications among lupus patients and controls: the Michigan Lupus Epidemiology and Surveillance Program. Arthritis Care Res 2021;73:1561-7.

Downloaded on October 6, 2026 from www.jrheum.org